Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.otohns.2006.08.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
NAB2::STAT6 Rearranged Carcinoma of the Parotid Gland with Sebaceous Differentiation: A Case Report.
Head Neck Pathol
January 2025
Department of Pathology, University Medical Center Utrecht, Utrecht, 3508 GA, The Netherlands.
Purpose: The NAB2::STAT6 fusion is predominantly associated with solitary fibrous tumors (SFTs) and is utilized in diagnosing SFTs through nuclear STAT6 protein overexpression. Recent studies expanded the phenotypic spectrum of NAB2::STAT6 rearranged neoplasms, including adamantinoma-like and teratocarcinosarcoma-like phenotypes. We report a case of a NAB2::STAT6 rearranged epithelial tumor exhibiting sebaceous differentiation in the parotid gland.
View Article and Find Full Text PDFSebaceous carcinoma in immunosuppressed patients: a narrative review.
Arch Dermatol Res
January 2025
Department of Dermatology, Columbia University Irving Medical Center, 161 Ft Washington Ave, 12th Floor, New York, NY, 10032, USA.
Sebaceous carcinoma is a rare cutaneous malignancy of sebaceous glands, but it is up to 25-fold more common in immunosuppressed individuals. In this narrative review, we examine the current literature on the pathogenesis, incidence, risk factors, prognosis, treatment, and surveillance of sebaceous carcinoma in immunosuppression and highlight practical considerations for providers who care for these patients. Increased incidence may be related to decreased immune surveillance, susceptibility to an unknown viral trigger, microsatellite instability, immunosuppressive medications, and unmasking of occult Muir-Torre Syndrome.
View Article and Find Full Text PDFSebaceous Carcinoma Arising in a Precursor Benign Sebaceoma: Rare Example Highlighting the Utility of Immunohistochemistry Including p53.
Am J Dermatopathol
November 2024
Cellular Pathology Department, Dorset County Hospital Foundation NHS Trust, Dorchester, United Kingdom.
Reports of sebaceous carcinoma arising from a pre-existing benign precursor are extremely sparse in the literature. We describe a case in which there was clear transition between sebaceoma and sebaceous carcinoma, with a different pattern of p53 staining in each component.
View Article and Find Full Text PDFPRAME Staining of Adnexal Lesions and Common Skin Cancer Types: Biomarker with Potential Diagnostic Utility.
Dermatopathology (Basel)
December 2024
Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA.
PRAME (PReferentially expressed Antigen in MElanoma) is a tumor-associated antigen first identified in tumor-reactive T-cell clones derived from a patient with metastatic melanoma. Immunohistochemistry (IHC) for PRAME is useful for diagnostic purposes to support a suspected diagnosis of melanoma. Anecdotally, PRAME has been observed to stain sebaceous units in glands in background skin.
View Article and Find Full Text PDFSurvival Outcomes of 997 Patients With Eyelid Sebaceous Carcinoma in the National Cancer Database.
J Craniofac Surg
December 2024
Department of Ophthalmology, University of CaliforniaIrvine, Irvine, CA.
Objectives: This study aimed to characterize the survival of patients with sebaceous carcinoma (SC) of the eyelids according to demographics and other variables.
Methods: Patients with SC of the eyelids from 2004 to 2017 were identified in the National Cancer Database. Demographic and clinical covariates were assessed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!